Melfalán Aspen (Melphalan)

Melphalan forms covalent cross‑links between DNA bases, preventing replication and transcription. This DNA damage halts the cell cycle and triggers programmed cell death, especially in rapidly dividing cancer cells, while sparing most normal tissues.

The specific dose of Melfalán Aspen is determined by the prescribing oncologist based on the patient’s diagnosis, disease stage, body surface area and renal function. Dosing regimens are individualized and should follow the prescriber’s instructions.

The safety of melphalan in pregnancy and lactation is not established. It is classified as contraindicated unless the potential therapeutic benefit justifies the potential risk to the fetus. Breastfeeding is generally not recommended while receiving melphalan.

To request Melfalán Aspen, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Melphalan shares the DNA‑cross‑linking mechanism of other alkylators such as cyclophosphamide, but it is more lipophilic and often used in high‑dose regimens for specific cancers like multiple myeloma. Its toxicity profile, especially myelosuppression and risk of secondary malignancies, may differ from agents with distinct metabolic pathways.

Melfalán Aspen should be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and potency.

Melfalán Aspen is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion rate and duration are set by the treating physician, and patients are monitored for immediate reactions during and after administration.

Serious risks include severe myelosuppression leading to infection or bleeding, secondary hematologic malignancies, hemorrhagic cystitis, pulmonary toxicity, and renal impairment. Prompt recognition and supportive care are essential to manage these complications.

Melfalán Aspen is contraindicated in patients with known hypersensitivity to melphalan or any component of the formulation, in those with severe renal impairment without dose adjustment, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for patients with active uncontrolled infections.